Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
06/2003
06/05/2003WO2003045383A1 Use of ppar activators for the treatment of pulmonary fibrosis
06/05/2003WO2003045382A1 Therapeutic compounds for treating dyslipidemic conditions
06/05/2003WO2003045380A1 Ilk inhibitors for the treatment of renal disease
06/05/2003WO2003045379A1 Hydrazonopyrazole derivatives and their use as therapeutics
06/05/2003WO2003045378A1 Amino acid derivatives useful for the treatment of alzheimer's disease
06/05/2003WO2003045377A1 Antioxidant dermatological composition
06/05/2003WO2003045376A1 Method for inhibiting overactivity of phagocytes or lymphocytes in an individual
06/05/2003WO2003045375A1 Novel utilization of cyclopentabenzofurans
06/05/2003WO2003045374A1 Treating asthma, chronic obstructive pulmonary disease and/or other respiratory difficulties
06/05/2003WO2003045373A1 Use of propionyl l-carnitine or one of its pharmacologically acceptable salts for the preparation of a medicine for the treatment of la peyronie's disease
06/05/2003WO2003045372A1 Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy
06/05/2003WO2003045371A1 Pharmaceutical compositions and methods for administering ep2 receptor selective agonists
06/05/2003WO2003045370A1 Pharmaceutical composition for treating obesity
06/05/2003WO2003045369A2 Use of l isomers of amino acid derivatives of hydroxyguanidine for producing no, pharmaceutical compositions containing same and pharmaceutical uses
06/05/2003WO2003045368A1 Pharmaceutical composition comprising a combination of metformin and a 4-oxobutanoic acid, and the use thereof for treating diabetes
06/05/2003WO2003045367A1 Angiogenesis inhibitor
06/05/2003WO2003045366A1 Treatment of wounds and compositions employed
06/05/2003WO2003045365A2 Sphingosine derivative as an immunoregulator compound
06/05/2003WO2003045364A2 Use of quinazolines to treat t-cell mediated diseases
06/05/2003WO2003045363A2 Treatment of th2 dominated immunological disease states with progesterone receptor antagonists
06/05/2003WO2003045362A2 Treatment of th1 dominated immunological disease states with non-endogenous gestagen compounds
06/05/2003WO2003045361A1 Prevention of miscarriage with immunomodulating non-endogenous gestagen compounds
06/05/2003WO2003045360A2 Use of gaba for the treatment of intestinal inflammations
06/05/2003WO2003045359A2 Combination of cimetidine and cysteine derivatives for treating cancer
06/05/2003WO2003045358A1 TRANSDERMAL THERAPEUTICAL SYSTEM FOR THE ADMINISTRATION OF 17α ESTRADIOL
06/05/2003WO2003045357A1 Oral pharmaceutical formulations comprising paclitaxel, derivatives and methods of administration thereof
06/05/2003WO2003045356A1 Pharmaceutical dosage form with multiple coatings
06/05/2003WO2003045355A1 Pharmaceutical compositions comprising metformine and glibenclamide for the treatment of type-ii diabetes mellitus
06/05/2003WO2003045354A1 Micropherules containing a pleuromutilin derivative
06/05/2003WO2003045351A1 Controlled release polymeric compositions of bone growth promoting compounds
06/05/2003WO2003045338A1 Compositions comprising phenyl-glycine derivatives
06/05/2003WO2003045334A2 Methods and compositions for ameliorating the undesirable effects of chemotherapy
06/05/2003WO2003045333A2 Treatment of hyperproliferative diseases using active vitamin d analogues
06/05/2003WO2003045332A2 Methods and compositions for treating lesions of the respiratory epithelium
06/05/2003WO2003045331A2 Formulations for oral administration of cromolyn sodium
06/05/2003WO2003045328A2 Methods of making and using theaflavin, theaflavin-3-gallate, theaflavin-3'-gallate and theaflavin 3,3'-digallate and mixtures thereof
06/05/2003WO2003045326A2 Method for preparing and using polyoxyethylated castor oil in pharmaceutical compositions
06/05/2003WO2003045319A2 Targeted therapeutics and uses thereof
06/05/2003WO2003045318A2 Manipulation of cytokine levels using cd83 gene products
06/05/2003WO2003045317A2 Therapeutic protein and treatments
06/05/2003WO2003045315A2 Carbonylbenzoxazine compounds for enhancing glutamatergic synaptic responses
06/05/2003WO2003045313A2 2-aminoquinoline compounds
06/05/2003WO2003045312A2 Biosynthetic gene cluster for the maytansinoid antitumor agent ansamitocin
06/05/2003WO2003045307A2 Pharmaceutical formulations comprising indolinone derivatives
06/05/2003WO2003045306A2 Phenoxy amine compounds and compositions for delivering active agents
06/05/2003WO2003045305A2 Acetaminophen compositions
06/05/2003WO2003045272A2 ORAL IMMUNOSTIMULATION OF MAMMALS, BIRDS, FISH AND REPTILES FROM (1-4) LINKED ß-D-MANNURONIC ACID
06/05/2003WO2003045228A2 Methods for treating autoimmune disorders, and reagents related thereto
06/05/2003WO2003045227A2 Single nucleotide polymorphisms and combinations thereof predictive for paclitaxel responsiveness
06/05/2003WO2003045225A2 Composition and method for treating the over-production of mucin in diseases such as otitis media using an inhibitor of muc5ac
06/05/2003WO2003045168A1 Powder formulation comprising conjugated octadecapolyenic acids
06/05/2003WO2003045162A1 Method of fattening poultry
06/05/2003WO2003045153A1 Combination bacteriolytic therapy for the treatment of tumors
06/05/2003WO2003045136A1 Disruption of the prostaglandin e synthase 2 gene
06/05/2003WO2003037309A3 USE OF 4α PHORBOL
06/05/2003WO2003035043A3 Pharmaceutical formulation comprising more than 15% tamoxifen
06/05/2003WO2003032974A3 Use of sulfonamide derivatives as pharmaceuticals compounds
06/05/2003WO2003020241A9 Functional powders for oral delivery
06/05/2003WO2003014094A3 Heterocyclic aryl sulphonamides
06/05/2003WO2003011266A3 Azalide antibiotic compositions
06/05/2003WO2003008430A3 Porphyrin derivatives for photodynamic therapy
06/05/2003WO2003005951A3 Drug delivery system for zero order, zero order-biphasic, ascending or descending drug delivery
06/05/2003WO2002102306A3 Methods and compositions for inhibiting, preventing, or reducing tumor cell growth in patients resistant to the antineoplastic effects of antiestrogen therapy
06/05/2003WO2002091988A3 Novel processes for the preparation of adenosine compounds and intermediates thereto
06/05/2003WO2002085843A3 Process for the preparation of 1,3-substituted indenes and aryl-fused azapolycyclic compounds
06/05/2003WO2002081665A3 Implantation serine proteinases
06/05/2003WO2002074275A3 Systems for delivering a cosmetic and/or therapeutic active to oral surfaces
06/05/2003WO2002074099A3 Polybutene containing chewing gum and confection
06/05/2003WO2002069949A3 Combination therapy for reduction of toxycity of chemotherapeutic agents
06/05/2003WO2002068548A3 Use of erss-selective ligands for regulating fertility and compounds useful therefore
06/05/2003WO2002064157A9 Localized myocardial injection method for treating ischemic myocardium
06/05/2003WO2002060932A3 A serpin in bifidobacteria
06/05/2003WO2002060864A9 Process of obtaining compositions of stable lutein and lutein derivatives
06/05/2003WO2002058712A3 Probiotic compounds derived from lactobacillus casei strain ke01
06/05/2003WO2002048124A3 Piperazine derivatives
06/05/2003WO2002036075A3 Small molecule compositions for binding to hsp90
06/05/2003WO2002031514A3 A method of determining the initial dose of vitamin d compounds
06/05/2003WO2002028863A8 New oxabispidine compound useful in the treatment of cardiac arrhythmias
06/05/2003WO2002009718A3 Agents containing corticosteroids for reducing graft rejection reactions
06/05/2003WO2001064899A9 Nucleotide sequences encoding proteins that take part in the biosynthesis of l-serine, improved method for microbially producing l-serine, and genetically modified microorganism suitable for use in said method
06/05/2003US20030106085 Disruption of the prostaglandin E synthase 2 gene
06/05/2003US20030105360 Polymorphic; for inhibiting serotonin uptake in mammals
06/05/2003US20030105359 Having good thermal stability and/or solubility characterisitics
06/05/2003US20030105357 Polycyclic dianthraquinones such as hyperycins and helianthrones as inhibitors of angiogenesis
06/05/2003US20030105339 Psoralen compounds with aminoalkyl groups on the 5' position and optional alkyl groups on positions 4,4' and 8 that bind to nucleic acid of pathogens, and under photoactivation crosslink the nucleic acid, inactivating the pathogen
06/05/2003US20030105336 Pyrazole derivatives, their preparation and their use in pharmaceuticals
06/05/2003US20030105333 RXR activating molecules
06/05/2003US20030105331 Use as anorectics, treating obesity and type II diabetes; C2-substituent is a sulfonyl-, sulfinyl- or sulfide-containing group, and indan 1-hydroxy group is esterified, etherified or a carbonate group
06/05/2003US20030105330 Synthesis of epothilones, intermediates thereto and analogues thereof
06/05/2003US20030105329 Process for the production of piperidine derivatives
06/05/2003US20030105328 High effectiveness and high oral bioavailability; for example, 6-(4-Acetamidophenyl)-3-isobutyryl-5-(N-benzyl-N-methylaminomethyl)-1-(2',6'-difluorobenzyl)-1,4-dihydro-4-oxoquinoline
06/05/2003US20030105326 Chloride or bromide salts; use stimulating the immune system such as in vaccines, treating proliferative disorders, or microbial or parasitic infections
06/05/2003US20030105324 Camptothecin analogs and methods of preparation thereof
06/05/2003US20030105318 G-protein transmembrane domain; protein synthesis inhibitor; neurotransmitter
06/05/2003US20030105300 Carbocyanine dyes/bioconjugates; optical tomography; fluorescence endoscopy; treating atherosclerotic plaques and blood clots; laser detection of metastasis
06/05/2003US20030105168 Composition comprising ubiquinone
06/05/2003US20030105167 Using polycyclic phenolic compound
06/05/2003US20030105165 Gap junctions and EDHF
06/05/2003US20030105164 Reacting hexachloroacetone with triphenylphosphine; chlorination of retinoic acid; then aromatic amine; anticancer agents
06/05/2003US20030105163 Photochemotherapeutic method using 5-aminolevulinic acid and other precursors of endogenous porphyrins
1 ... 5444 5445 5446 5447 5448 5449 5450 5451 5452 5453 5454 5455 5456 5457 5458 5459 5460 5461 5462 5463 5464 ... 7860